BioCentury
ARTICLE | Financial News

uniQure raises $88.5M in follow-on

April 10, 2015 11:40 PM UTC

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $88.5 million through the sale of 3 million shares at $29.50 in a follow-on underwritten by Leerink; Cowen; Piper Jaffray; Oppenheimer; and H.C. Wainwright. uniQure proposed the offering after market on Tuesday, when its shares closed at $33.63. The stock lost $2.35 to $28.44 on Friday.

The biotech plans to begin a Phase IV U.S. study in early 2016 of Glybera alipogene tiparvovec before submitting a BLA to FDA. The adeno-associated virus (AAV) vector encoding lipoprotein lipase ( LPL) gene is approved in Europe to treat LPL deficiency in patients with acute, recurring pancreatitis. European partner Chiesi Farmaceutici S.p.A. (Parma, Italy) expects the first patient to receive Glybera in mid-2015. ...